You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微創腦科學(02172.HK)2023年淨溢利1.35億元 同比扭虧為盈
格隆匯 03-28 00:08

格隆匯3月28日丨微創腦科學(02172.HK)公吿,於截至2023年12月31日止年度,集團錄得收入人民幣6.66億元,同比增長21.6%。於2023財年,集團錄得淨溢利人民幣1.35億元,與2022財年相比,實現淨溢利扭虧為盈且增長強勁。於2023財年,集團錄得非《香港財務報吿準則》經調整淨溢利人民幣1.95億元,較2022財年的人民幣1.3億元增長49.5%。得益於上述收入及盈利的增加,董事會已決議建議派發2023財年末期股息每股普通股0.11港元。

集團已建立一支具有專業醫療背景且經驗豐富的治療方案推廣團隊,持續向市場輸出創新神經介入治療理念,為患者和醫生提供腦血管疾病一體化解決方案,包括術式和產品宣教、治療方案建議、手術及器械使用培訓、臨牀支持及術後跟蹤隨訪等,夯實國產品牌領先地位。

截至2023年末,公司的治療方案推廣團隊擁有85名員工,平均行業經驗超過12年。此外,本集團已與400家經銷商及二級經銷商建立合作關係,銷售渠道覆蓋全國31個省份、直轄市及自治區。本集團的產品累計在全國超過3,000家醫院獲得臨牀應用,涵蓋超過1,550家三級醫院及所有中國國家卒中中心排名前100的醫院,累計支持約167,000台神經介入手術。

2023年,得益於全面完善的產品矩陣和長期積累的術者認可,本集團產品新開拓超過400家醫院,其中縣級醫院佔約200家,逐步鞏固基層市場。與此同時,多個省份彈簧圈集中帶量採購項目陸續執行,河南省亦開展公立醫療機構神經介入醫用耗材帶量採購。本集團相關產品得益於集採中標,醫院准入和臨牀推廣迎來突破性進展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account